# Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure

> **NCT02232581** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 72 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Alovudine - low
- **DRUG:** Alovudine - medium
- **DRUG:** Alovudine - high
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02232581
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2004-12
- **Final completion:** —
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2014-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02232581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02232581, "Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02232581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*